# iRegene

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/iregene

- Industry: Biotechnology
- Headquarters: Chengdu, China
- Website: www.iregene.com
- Total disclosed funding: $99M
- Latest round: Series C (Jul 2, 2026)
- Investors on record: 21

## About

Based in Chengdu, China and founded in 2017, Ruijian Yilian Pharmaceutical Technology (Chengdu) Co., Ltd., trading as iRegene, is a biotechnology company that focuses on the development of small chemical molecules to induce functional cell regeneration drugs. The company has established bases in Wuhan, Suzhou, China, as well as in Danmark, Singapore and Australia. In 2019, the company completed pilot scale production of NouvNeu001, a pipeline for treating Parkinson's disease. In July 2026, iRegene raised CNY 260 million in series C+ funding led byChengdu Science and Technology Venture Capital Group, with participation fromChina Capital Management, Wuxi Innovation Investment Group, Qilu Pharmaceutical, Xinjiye, Hony Capital, GSR United Capital, and other investors.

iRegene focuses on the development of small chemical molecules to induce functional cell regeneration drugs to cure Parkinson’s disease and blindness. Leveraging its R&D platforms for discovering Omics, compounds validation, gene editing etc., that are powered by AI (Artificial Intelligence) and deep learning the company has developed multiple pipeline products for the treatment of Parkinson’s Disease, Multiple System Atrophy (MSA-P), Retinal Degenerative Diseases and Ischemic Stroke. 

The company generates revenue by developing new generation of chemically induced cell therapy products.

## Funding rounds

- Series C, Jul 2, 2026, $38M — Hony Capital, Chengdu Science and Technology Venture Capital Group, China Capital Management, GSR United Capital, Qilu Pharmaceuical, Wuxi Innovation Investment Group, Xinjiye
- Series C, Jun 1, 2026, $31M — Guanghe VC, Apricot Capital
- Series C, Mar 18, 2026 — Vertex Ventures China
- Series B, Sep 4, 2025 — NLVC, GSR United Capital, Chuangjing Capital
- Series B, Apr 11, 2025 — Lotus Lake Capital, FC Capital - China
- Series B, Oct 14, 2024, $14M — Optics Valley Industrial Investment Fund Management, BIO-TOWN Capital, Orinno Capital
- Series A, Aug 11, 2021, $15M — Fortune Capital, Jiuyo Capital
- Angel, Jan 1, 2019 — Huafang Capital, Guanggu Rencai Fund

## Investors

- Huafang Capital (https://capitalatlas.ai/funds/huafang-capital) — Angel
- Guanggu Rencai Fund (https://capitalatlas.ai/funds/guanggu-rencai-fund) — Angel
- Fortune Capital — Series A
- Jiuyo Capital (https://capitalatlas.ai/funds/jiuyo-capital) — Series A
- Optics Valley Industrial Investment Fund Management (https://capitalatlas.ai/funds/optics-valley-industrial-investment-fund-management) — Series B
- BIO-TOWN Capital (https://capitalatlas.ai/funds/bio-town-capital) — Series B
- Orinno Capital (https://capitalatlas.ai/funds/orinno-capital) — Series B
- Lotus Lake Capital (https://capitalatlas.ai/funds/lotus-lake-capital) — Series B
- FC Capital - China (https://capitalatlas.ai/funds/fc-capital-china) — Series B
- NLVC (https://capitalatlas.ai/funds/nlvc) — Series B
- GSR United Capital (https://capitalatlas.ai/funds/gsr-united-capital) — Series B, Series C
- Chuangjing Capital (https://capitalatlas.ai/funds/chuangjing-capital) — Series B
- Vertex Ventures China (https://capitalatlas.ai/funds/vertex-ventures-china) — Series C
- Guanghe VC (https://capitalatlas.ai/funds/guanghe-vc) — Series C
- Apricot Capital (https://capitalatlas.ai/funds/apricot-capital) — Series C
- Hony Capital (https://capitalatlas.ai/funds/hony-capital) — Series C
- Chengdu Science and Technology Venture Capital Group (https://capitalatlas.ai/funds/chengdu-science-and-technology-venture-capital-group) — Series C
- China Capital Management (https://capitalatlas.ai/funds/china-capital-management) — Series C
- Qilu Pharmaceuical — Series C
- Wuxi Innovation Investment Group — Series C
- Xinjiye — Series C